{"gene":"PRDX5","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":1999,"finding":"PRDX5 (originally named AOEB166) was identified as a novel mammalian peroxiredoxin with peroxidase activity. Recombinant AOEB166 expressed in E. coli exhibits peroxidase activity and antioxidant activity comparable to catalase. The protein contains both mitochondrial and peroxisomal targeting sequences, and GFP-fusion protein expressed in HepG2 cells is sorted to both organelles.","method":"Recombinant protein expression in E. coli, glutamine synthetase protection assay, GFP fusion subcellular localization in HepG2 cells, mRNA distribution analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic assay plus direct subcellular localization experiment","pmids":["10521424"],"is_preprint":false},{"year":1999,"finding":"Human PMP20 (PRDX5 ortholog) localizes to peroxisomes via a C-terminal PTS1 signal (SQL tripeptide) that binds the peroxisomal targeting signal receptor HsPEX5; mutagenesis of the SQL sequence abolishes binding to HsPEX5. HsPMP20 exhibits thiol-specific antioxidant activity (inhibiting glutamine synthetase inactivation in thiol-dependent oxidation system) and thiol-peroxidase activity removing H2O2.","method":"Mutagenesis analysis, direct binding assay to HsPEX5, subcellular fractionation, double-staining immunofluorescence, glutamine synthetase protection assay, thiol-peroxidase activity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution of peroxisomal import mechanism with mutagenesis validation plus in vitro enzymatic assays","pmids":["10514471"],"is_preprint":false},{"year":2000,"finding":"PrxV (PRDX5) forms an intramolecular disulfide as a reaction intermediate during peroxide reduction, distinguishing it from other peroxiredoxins that form intermolecular disulfides or sulfenic acid intermediates. Cys48 is the peroxidatic site oxidized by peroxides, and oxidized Cys48 reacts with Cys152 to form an intramolecular disulfide. The disulfide is reduced by thioredoxin but not by glutaredoxin or glutathione. PRDX5 is localized to cytosol, mitochondria, and peroxisomes. Overexpression of wild-type but not Cys48 mutant inhibited H2O2 accumulation and c-Jun N-terminal kinase activation induced by TNF-alpha in NIH 3T3 cells.","method":"Site-directed mutagenesis of each Cys residue, thioredoxin-dependent peroxidase activity assay, immunoblot analysis of tissue distribution, subcellular localization by fractionation, transient overexpression with H2O2 and JNK activation readouts","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic assay with mutagenesis of catalytic residues plus functional cellular readout","pmids":["10751410"],"is_preprint":false},{"year":2000,"finding":"Mouse peroxiredoxin V (PRDX5) is a thioredoxin peroxidase that inhibits p53-induced apoptosis. Overexpression of Prx-V prevented p53-dependent generation of reactive oxygen species and inhibited p53-induced apoptosis in mammalian cells.","method":"Overexpression in mammalian cells, ROS measurement, apoptosis assay, thioredoxin peroxidase activity assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — clean overexpression with defined cellular phenotype (ROS suppression, apoptosis inhibition) but single lab, limited mechanistic detail","pmids":["10679306"],"is_preprint":false},{"year":2001,"finding":"The 1.5 Å crystal structure of human PRDX5 in reduced form reveals a thioredoxin-like domain. Unlike other mammalian peroxiredoxins, PRDX5 does not form a homodimer. In the reduced form, the catalytic Cys47 and Cys151 are 13.8 Å apart, indicating a conformational change is required to form the intramolecular disulfide upon oxidation. A benzoate ion was found near the active-site pocket.","method":"X-ray crystallography at 1.5 Å resolution","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure revealing catalytic mechanism and unique structural features","pmids":["11518528"],"is_preprint":false},{"year":2003,"finding":"PRDX5 is classified as the atypical 2-Cys peroxiredoxin: it uses an active-site cysteine (peroxidatic Cys) oxidized to sulfenic acid by peroxide substrate, then forms an intramolecular disulfide with the resolving Cys, recycled by thioredoxin. This mechanism is distinct from typical 2-Cys Prxs (intermolecular disulfide) and 1-Cys Prxs.","method":"Biochemical analysis and crystal structure review; mechanistic classification based on structural and mutational data","journal":"Trends in biochemical sciences","confidence":"High","confidence_rationale":"Tier 1 — review synthesizing crystal structure and mutagenesis data, widely replicated mechanistic framework","pmids":["12517450"],"is_preprint":false},{"year":2004,"finding":"Human PRDX5 is a peroxynitrite reductase. The nucleophilic attack on the O-O bond of peroxynitrite is performed by the N-terminal peroxidatic Cys47. Using pulse radiolysis, the rate constant for peroxynitrite reduction was measured at (7±3)×10^7 M⁻¹s⁻¹, among the highest reported for any peroxynitrite reductase.","method":"Cysteine mutant analysis, pulse radiolysis to determine rate constant","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 — pulse radiolysis (direct kinetic measurement) combined with mutagenesis identifying catalytic residue","pmids":["15280035"],"is_preprint":false},{"year":2011,"finding":"PRDX5 is the unique atypical 2-Cys peroxiredoxin in mammals, localized to mitochondria, peroxisomes, cytosol, and nucleus. It reduces alkyl hydroperoxides and peroxynitrite using cytosolic or mitochondrial thioredoxins with rate constants of 10^6–10^7 M⁻¹s⁻¹, while reduction of H2O2 is more modest (~10^5 M⁻¹s⁻¹). Overexpression in different subcellular compartments protects cells from nitro-oxidative stress, while gene silencing increases vulnerability.","method":"Biochemical kinetic assays, subcellular fractionation, overexpression and knockdown with cell viability readouts (comprehensive review of accumulated experimental data)","journal":"Antioxidants & redox signaling","confidence":"High","confidence_rationale":"Tier 1–2 — synthesis of multiple independent in vitro and cellular experiments across multiple labs","pmids":["20977338"],"is_preprint":false},{"year":2010,"finding":"Prdx5 overexpression via adenoviral vector in small-for-size liver grafts during transplantation attenuated graft injury and increased recipient survival, demonstrating a protective role of Prdx5 in ischemia-reperfusion injury in vivo.","method":"Adenoviral overexpression in rat liver transplantation model, proteomics (2D-PAGE/MALDI-TOF), Western blotting, immunohistochemistry, survival analysis","journal":"Journal of hepatology","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo gain-of-function with defined phenotype (reduced injury, increased survival) but limited mechanistic pathway placement","pmids":["20451279"],"is_preprint":false},{"year":2020,"finding":"PRDX5 was identified as a novel binding partner of Nrf2 in NSCLC cells under H2O2-stimulated oxidative stress. The PRDX5–Nrf2 interaction promotes expression of NQO1 in NSCLC cells. Knockdown of both Nrf2 and PRDX5 significantly reduced tumor growth in animal models.","method":"Co-immunoprecipitation, Western blotting, shRNA knockdown, animal tumor growth assays","journal":"Aging","confidence":"Medium","confidence_rationale":"Tier 2–3 — Co-IP demonstrating interaction plus in vivo functional validation, single lab","pmids":["31899687"],"is_preprint":false},{"year":2020,"finding":"ROS-induced hypomethylation of the PRDX5 promoter enhances STAT3 binding at two specific sites (−444 to −434 bp and −1417 to −1407 bp), increasing PRDX5 expression. STAT3 knockdown decreased PRDX5 protein levels while STAT3 overexpression increased them. PRDX5 overexpression activated the Nrf2 signaling pathway and promoted EMT (decreased E-cadherin, increased vimentin) in NSCLC cells under oxidative stress.","method":"Bisulfite sequencing PCR, ChIP assay, luciferase detection assay, STAT3 knockdown/overexpression, siRNA and pcDNA3.1 transfection with Western blotting","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP confirms direct STAT3 binding at PRDX5 promoter; multiple orthogonal methods in single lab","pmids":["33416106"],"is_preprint":false},{"year":2023,"finding":"PRDX5 regulates the DNA damage response (DDR) through multiple mechanisms: (1) Plk1-mediated phosphorylation of ATM kinase triggering downstream Chek1/Chek2; (2) regulation of p53 acetylation at lysine 382 via Sirt2, which was identified as a novel deacetylase of p53 at K382 in a Prdx5-dependent manner; (3) induction of autophagy that recycles DDR molecules. Prdx5 knockdown induced γ-H2AX and 53BP1 (DNA damage markers), while exogenous Prdx5 decreased DNA damage and ATM activation in Pkd1 mutant renal epithelial cells.","method":"siRNA knockdown, γ-H2AX and 53BP1 immunofluorescence, Western blotting for phospho-ATM/Chek1/Chek2, p53 acetylation assays, autophagy assays, exogenous PRDX5 expression in Pkd1 mutant cells","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods establishing pathway position (ATM/p53/Sirt2), single lab","pmids":["36067023"],"is_preprint":false},{"year":2023,"finding":"PRDX5 promotes AR inhibitor resistance and castration-resistant prostate cancer (CRPC) development. The thioredoxin/peroxiredoxin pathway is upregulated in drug-tolerant persister (DTP) cells. Inhibition of PRDX5 suppresses DTP cell proliferation in culture and dampens CRPC development in animal models.","method":"Cell culture proliferation assays, animal models of CRPC, pathway analysis, PRDX5 inhibition","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with defined cellular and in vivo phenotype, supported by patient data","pmids":["38115765"],"is_preprint":false},{"year":2023,"finding":"PRDX5 and Nrf2 form a protein complex that is enhanced by oxidative stress (H2O2 treatment). The PRDX5–Nrf2 complex synergistically promotes NSCLC cell proliferation and drug resistance in zebrafish models.","method":"Co-immunoprecipitation, Western blotting, immunohistochemistry, zebrafish xenograft models","journal":"Oncology research","confidence":"Medium","confidence_rationale":"Tier 3 — Co-IP confirms complex; zebrafish functional validation; single lab","pmids":["37305326"],"is_preprint":false},{"year":2025,"finding":"During cryopreservation-induced oxidative stress in bull sperm, PRDX5 translocates intracellularly and forms high molecular weight oligomers that may shift from peroxidase to chaperone roles. PRDX5 interaction with TLR4 may be key to its intracellular transport. PRDX5 is also found in exosomal vesicles, suggesting a potential transport mechanism.","method":"Imaging Flow Cytometry, native PAGE and SDS-PAGE techniques (various), ROS/NO measurement, mitochondrial potential assay, DNA fragmentation assay","journal":"Cell communication and signaling","confidence":"Low","confidence_rationale":"Tier 3 — single lab, translocation and oligomerization observed but mechanistic link to TLR4 is correlative","pmids":["39780184"],"is_preprint":false},{"year":2025,"finding":"PRDX5 regulates mitochondrial function and myonuclear positioning during myogenesis. Prdx5-/- myotubes exhibit impaired nuclear spreading (clustered nuclei) and reduced mitochondrial ATP production. PRDX5 facilitates mitochondrial transport and nuclear positioning at least in part through transcriptional regulation of Rhot1 and Trak1 (key mitochondrial transport regulators). Double knockout of Prdx3 and Prdx5 accelerates muscle aging with increased mitochondrial H2O2 production, upregulating E3 ligases Atrogin1 and MuRF1.","method":"Prdx5-/- and Prdx3-/-;Prdx5-/- mouse models, confocal and super-resolution lattice SIM microscopy, Seahorse OCR assays, Rhot1/Trak1 knockdown, grip strength, treadmill performance, histology","journal":"Journal of cachexia, sarcopenia and muscle","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout with multiple orthogonal methods, mechanistic linkage to mitochondrial transport via Rhot1/Trak1 validated by independent knockdown","pmids":["41147088"],"is_preprint":false},{"year":2025,"finding":"IER3 inhibits mitochondrial translocation of PRDX5 by interacting with the presenilin-associated rhomboid-like protease (Parl) and reducing its shear activity, thereby preventing cleavage and mitochondrial import of cytoplasmic PRDX5. Reduced mitochondrial PRDX5 impairs antioxidant capacity, causes oxidative mitochondrial damage and abnormal perinuclear mitochondrial clustering, promoting RTEC stress-induced senescence and AKI-to-CKD transition.","method":"IER3 knockout mice, RNA-seq, PRDX5 inhibition rescue experiments, co-immunoprecipitation (IER3–Parl interaction), mitochondrial fractionation, senescence assays","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO plus Co-IP identifying IER3–Parl–PRDX5 axis; single lab but multiple orthogonal approaches","pmids":["41359162"],"is_preprint":false},{"year":2025,"finding":"PRDX5 interacts with TFAM; PRDX5 overexpression enhances TFAM activation to counteract ROS-induced mitochondrial damage and restore mitochondrial homeostasis in renal tubular cells. TFAM knockdown reverses the mitochondrial functional improvements achieved through PRDX5 overexpression.","method":"Protein binding assays (PRDX5–TFAM interaction), ultrasound microbubble-mediated in situ PRDX5 overexpression, PRDX5 knockdown, TFAM knockdown, mtDNA leakage assay, mitochondrial function assays in CKD models","journal":"Phytomedicine","confidence":"Low","confidence_rationale":"Tier 3 — protein interaction identified but mechanistic detail of PRDX5–TFAM interaction limited; single lab","pmids":["39955823"],"is_preprint":false},{"year":2025,"finding":"SIRT3 activates PRDX5 as its direct downstream effector in neurons; SIRT3 and PRDX5 co-localize in the anterior horn spinal cord neurons. Genetic silencing of PRDX5 partially attenuated SIRT3-mediated neuroprotection against apoptosis after spinal cord injury, placing PRDX5 downstream of SIRT3 in a neuroprotective axis.","method":"Transcriptome analysis of Sirt3-/- mice, SIRT3 agonist (honokiol) treatment, PRDX5 siRNA knockdown, immunofluorescence co-localization, neurological functional assessments in SCI mouse model","journal":"Brain research bulletin","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis established by transcriptomics + genetic silencing rescue experiment; single lab","pmids":["40818507"],"is_preprint":false},{"year":2025,"finding":"Prdx5 promotes M1 macrophage polarization and apoptosis of prostate epithelial cells via the TLR4/NF-κB signaling pathway in an ROS-dependent manner. Prdx5 silencing suppressed M1 polarization, reduced epithelial cell apoptosis, and mitigated experimental autoimmune prostatitis. Prdx5 expression in macrophages is regulated in an ROS-dependent manner.","method":"Prdx5 siRNA silencing, Western blotting, RT-qPCR, flow cytometry, cell co-culture, immunofluorescence staining, EAP mouse model","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with defined pathway (TLR4/NF-κB) and cellular phenotype (M1 polarization), single lab","pmids":["40015209"],"is_preprint":false},{"year":2026,"finding":"Acetylation of PRDX5 inhibits its antioxidant and anti-apoptotic functions. OGD/R increased PRDX5 acetylation in retinal neurons; NAM treatment that increased acetylation elevated ROS and apoptosis, while NRC treatment that reduced acetylation decreased ROS and apoptosis. Inhibiting deacetylation abolished the protective effect of PRDX5 overexpression, demonstrating that acetylation status directly controls PRDX5 activity.","method":"OGD/R model in R28 cells, aHIOP mouse model, nicotinamide and NRC pharmacological modulation of acetylation, PRDX5 knockdown and overexpression, ROS measurement, mitochondrial membrane potential, TUNEL/PI staining, LDH release","journal":"Tissue & cell","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological modulation of acetylation with functional readout; identity of acetylase/deacetylase not fully established; single lab","pmids":["41740330"],"is_preprint":false},{"year":2025,"finding":"Salvianolic acid B (SAB) binds directly to PRDX5 (confirmed by DARTS, CETSA, and molecular docking) and enhances its redox activity, which in turn potentiates SLC7A11 and GPX4 inhibitory effects on ferroptosis. PRDX5 silencing partially abrogated SAB's protective effects on cisplatin-induced acute kidney injury.","method":"DARTS (drug affinity responsive target stability), CETSA (cellular thermal shift assay), molecular docking, PRDX5 siRNA knockdown, cisplatin- and folic acid-induced AKI models in vivo and in vitro","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 1–2 — direct binding confirmed by multiple biophysical methods plus functional rescue experiment; single lab","pmids":["40654183"],"is_preprint":false},{"year":2024,"finding":"Stachyose (STA) inhibits PRDX5 enzyme activity and disrupts the PRDX5–NRF2 protein–protein interaction, leading to decreased NQO1 levels and accumulation of quinone radicals, ultimately inducing apoptosis of AR-inhibitor drug-tolerant persister cells and slowing CRPC progression.","method":"PRDX5 enzyme activity assay, PRDX5–NRF2 interaction disruption assay, NQO1 Western blotting, apoptosis assay, pharmacokinetic analysis in CRPC mouse model","journal":"International journal of biological macromolecules","confidence":"Medium","confidence_rationale":"Tier 2 — direct enzymatic inhibition demonstrated plus mechanistic downstream pathway validated in vivo; single lab","pmids":["39168191"],"is_preprint":false},{"year":2022,"finding":"Porcine PRDX5 (pPRDX5) inhibits inflammatory responses induced by TNF-α or PRRSV in porcine alveolar macrophages. Knockdown of endogenous pPRDX5 enhanced inflammatory responses. The anti-inflammatory activity of pPRDX5 depends on its peroxidase activity, as shown by activity-dependent modulation experiments.","method":"Recombinant pPRDX5 protein treatment, siRNA knockdown of endogenous pPRDX5, TNF-α and PRRSV stimulation, inflammatory marker measurement, peroxidase activity assays","journal":"Developmental and comparative immunology","confidence":"Medium","confidence_rationale":"Tier 2 — gain- and loss-of-function with mechanistic link to peroxidase activity; ortholog but functional context consistent with mammalian PRDX5","pmids":["35985565"],"is_preprint":false}],"current_model":"PRDX5 is the unique atypical 2-Cys peroxiredoxin in mammals that reduces alkyl hydroperoxides, H2O2, and peroxynitrite (rate constant ~10^7 M⁻¹s⁻¹) via a catalytic cycle in which the peroxidatic Cys47 is oxidized by the peroxide substrate and then forms an intramolecular disulfide with the resolving Cys152, recycled by thioredoxin but not glutaredoxin; its 1.5 Å crystal structure confirmed the thioredoxin-fold monomer and the 13.8 Å separation of the two catalytic cysteines requiring a conformational change upon oxidation; PRDX5 is targeted to mitochondria, peroxisomes, cytosol, and nucleus by distinct targeting sequences, and functionally protects cells from nitro-oxidative stress, suppresses TNF-α-induced JNK activation and p53-induced apoptosis, regulates the DNA damage response through the ATM/Plk1/Sirt2/p53 axis, coordinates mitochondrial transport (via Rhot1/Trak1) and myonuclear positioning during myogenesis, acts downstream of SIRT3 in neuronal protection, modulates M1 macrophage polarization via TLR4/NF-κB, and physically interacts with Nrf2 to promote NQO1 expression and drug resistance in cancer; acetylation of PRDX5 inhibits its antioxidant activity, and its mitochondrial translocation is controlled by IER3 via the Parl protease."},"narrative":{"teleology":[{"year":1999,"claim":"Identification of PRDX5 as a novel mammalian peroxiredoxin with dual mitochondrial and peroxisomal targeting established that mammals possess a peroxiredoxin distinct from the known typical 2-Cys family members, with peroxisomal import mediated by PTS1 signal recognition by PEX5.","evidence":"Recombinant expression, GFP-fusion localization in HepG2, PEX5 binding assays with PTS1 mutagenesis","pmids":["10521424","10514471"],"confidence":"High","gaps":["Cytosolic and nuclear targeting mechanisms not yet defined","Endogenous substrates in each compartment unknown"]},{"year":2000,"claim":"Defining the atypical 2-Cys catalytic mechanism — intramolecular disulfide between Cys48 and Cys152, recycled by thioredoxin but not glutaredoxin — resolved how PRDX5 differs mechanistically from all other mammalian peroxiredoxins and established its first cellular function: suppression of TNF-α–induced JNK activation and p53-induced apoptosis.","evidence":"Site-directed mutagenesis of each Cys, thioredoxin-dependent peroxidase assays, overexpression in NIH 3T3 (JNK readout) and mammalian cells (p53-apoptosis readout)","pmids":["10751410","10679306"],"confidence":"High","gaps":["Structural basis for intramolecular disulfide formation not yet available","Mechanism of p53-apoptosis inhibition beyond ROS scavenging unclear"]},{"year":2001,"claim":"The 1.5 Å crystal structure of reduced PRDX5 revealed a thioredoxin-fold monomer with 13.8 Å separation between catalytic cysteines, demonstrating that a major conformational change must accompany oxidation — explaining why the enzyme is monomeric rather than forming the obligate dimers seen in typical 2-Cys peroxiredoxins.","evidence":"X-ray crystallography at 1.5 Å resolution","pmids":["11518528"],"confidence":"High","gaps":["Oxidized-form structure not captured","Conformational dynamics during catalysis unresolved"]},{"year":2004,"claim":"Pulse radiolysis measurement of the peroxynitrite reduction rate constant (~7×10⁷ M⁻¹s⁻¹) established PRDX5 as one of the fastest biological peroxynitrite reductases, expanding its functional role from H₂O₂ scavenging to reactive nitrogen species defense.","evidence":"Pulse radiolysis kinetics with Cys mutants","pmids":["15280035"],"confidence":"High","gaps":["Relative contribution to peroxynitrite scavenging in vivo versus other reductases untested","Compartment-specific kinetics not measured"]},{"year":2010,"claim":"In vivo gain-of-function via adenoviral PRDX5 overexpression in rat liver transplantation demonstrated that PRDX5 protects against ischemia-reperfusion injury, extending its antioxidant role to a whole-organ pathological context.","evidence":"Adenoviral overexpression in small-for-size rat liver grafts with survival analysis","pmids":["20451279"],"confidence":"Medium","gaps":["Downstream signaling pathway mediating hepatoprotection not defined","Loss-of-function in this model not performed"]},{"year":2020,"claim":"Discovery of the PRDX5–Nrf2 physical interaction revealed a non-canonical signaling role: PRDX5 promotes NQO1 expression under oxidative stress, and STAT3 transcriptionally upregulates PRDX5 via promoter hypomethylation, positioning PRDX5 within a STAT3→PRDX5→Nrf2 signaling axis that promotes EMT and drug resistance in NSCLC.","evidence":"Co-immunoprecipitation, ChIP for STAT3 binding at PRDX5 promoter, bisulfite sequencing, siRNA/overexpression with EMT markers","pmids":["31899687","33416106"],"confidence":"Medium","gaps":["Binding interface between PRDX5 and Nrf2 unmapped","Whether PRDX5 redox activity is required for Nrf2 interaction unknown","Reciprocal Co-IP for PRDX5–Nrf2 not shown in original report"]},{"year":2022,"claim":"Porcine PRDX5 demonstrated peroxidase-activity-dependent anti-inflammatory function in macrophages stimulated with TNF-α or PRRSV, providing direct evidence that PRDX5's enzymatic activity (not merely protein presence) underlies its immunomodulatory effects.","evidence":"Recombinant protein treatment and siRNA knockdown in porcine alveolar macrophages with peroxidase activity-dependence assays","pmids":["35985565"],"confidence":"Medium","gaps":["Mechanism linking peroxidase activity to inflammatory signaling not identified","Cross-species generalizability to human macrophages not confirmed"]},{"year":2023,"claim":"PRDX5 was placed within the DNA damage response pathway operating through ATM/Plk1/Sirt2/p53, with Sirt2 identified as a novel PRDX5-dependent p53 K382 deacetylase, and separately shown to promote castration-resistant prostate cancer via its role in drug-tolerant persister cell survival.","evidence":"siRNA knockdown with γ-H2AX/53BP1 readouts, p53 acetylation assays in Pkd1 mutant cells; PRDX5 inhibition in CRPC animal models","pmids":["36067023","38115765"],"confidence":"Medium","gaps":["Direct physical interaction between PRDX5 and Sirt2 not demonstrated","How PRDX5 peroxidase activity connects to DDR signaling mechanistically unclear","Whether DDR and CRPC roles converge on a shared mechanism unknown"]},{"year":2024,"claim":"Pharmacological disruption of the PRDX5–NRF2 protein–protein interaction by stachyose validated this complex as a druggable node: inhibiting PRDX5 enzymatic activity and NRF2 binding decreased NQO1 levels and induced apoptosis of drug-resistant persister cells in CRPC models.","evidence":"Enzyme activity assays, interaction disruption assays, NQO1 immunoblotting, apoptosis readout, CRPC mouse pharmacokinetics","pmids":["39168191"],"confidence":"Medium","gaps":["Structural basis of stachyose–PRDX5 binding undefined","Selectivity of stachyose for PRDX5 over other peroxiredoxins untested"]},{"year":2025,"claim":"Multiple 2025 studies expanded PRDX5 from a simple antioxidant to a multifunctional signaling hub: genetic knockout revealed its requirement for mitochondrial transport (Rhot1/Trak1) and myonuclear positioning during myogenesis; epistasis experiments placed it downstream of SIRT3 in neuroprotection; IER3 was shown to control its mitochondrial import via Parl protease; and acetylation was identified as a direct negative regulator of its activity.","evidence":"Prdx5⁻/⁻ and Prdx3⁻/⁻;Prdx5⁻/⁻ mice with Seahorse/microscopy/Rhot1-Trak1 knockdown; SIRT3 agonist plus PRDX5 siRNA epistasis in SCI model; IER3 KO mice with Co-IP of IER3–Parl; OGD/R with acetylation modulation in retinal neurons; TLR4/NF-κB pathway in macrophage polarization","pmids":["41147088","40818507","41359162","41740330","40015209"],"confidence":"Medium","gaps":["Acetylation site(s) on PRDX5 not mapped","Whether SIRT3 directly deacetylates PRDX5 not tested","How Parl cleavage enables mitochondrial import structurally unresolved","Integration of myogenesis and immune roles into a unified regulatory model lacking"]},{"year":null,"claim":"Key open questions include: the identity of the acetyltransferase/deacetylase pair controlling PRDX5 activity, the structural basis of the PRDX5–Nrf2 interaction and whether it requires PRDX5's redox state, the oxidized-form crystal structure capturing the conformational change, and how PRDX5's compartment-specific functions are differentially regulated.","evidence":"","pmids":[],"confidence":"High","gaps":["No oxidized-state crystal structure available","Acetylation sites and modifying enzymes unidentified","Compartment-specific knockout or targeting studies lacking","PRDX5–Nrf2 binding interface and redox dependence unmapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016209","term_label":"antioxidant activity","supporting_discovery_ids":[0,1,2,5,6,7]},{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,2,6,7]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[9,11,19]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,2,7,15,16]},{"term_id":"GO:0005777","term_label":"peroxisome","supporting_discovery_ids":[0,1,7]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,7]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[7]}],"pathway":[{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[2,7,8,20]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[3,20]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[19,23]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[11]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[9,10,19]}],"complexes":[],"partners":["NRF2","TFAM","SIRT3","PARL","IER3","TLR4","PEX5"],"other_free_text":[]},"mechanistic_narrative":"PRDX5 is the sole mammalian atypical 2-Cys peroxiredoxin, functioning as a broad-spectrum peroxidase that reduces alkyl hydroperoxides, H₂O₂, and peroxynitrite (rate constant ~10⁷ M⁻¹s⁻¹) through a catalytic cycle in which the peroxidatic Cys47 is oxidized to sulfenic acid, forms an intramolecular disulfide with the resolving Cys152 (separated by 13.8 Å in the reduced crystal structure, requiring conformational change), and is recycled by thioredoxin [PMID:10751410, PMID:11518528, PMID:15280035]. Distributed across mitochondria, peroxisomes, cytosol, and nucleus via distinct targeting sequences, PRDX5 protects cells from nitro-oxidative stress and suppresses TNF-α–induced JNK activation and p53-induced apoptosis; its mitochondrial import is controlled by IER3 through the Parl protease, and its activity is negatively regulated by acetylation [PMID:10521424, PMID:10751410, PMID:41359162, PMID:41740330]. Beyond canonical antioxidant defense, PRDX5 physically interacts with Nrf2 to promote NQO1 expression and drug resistance in cancer, operates downstream of SIRT3 in neuroprotection, modulates M1 macrophage polarization via TLR4/NF-κB, regulates the DNA damage response through the ATM/Plk1/Sirt2/p53 axis, and coordinates mitochondrial transport and myonuclear positioning during myogenesis through transcriptional regulation of Rhot1 and Trak1 [PMID:31899687, PMID:36067023, PMID:40818507, PMID:40015209, PMID:41147088]. PRDX5 upregulation in drug-tolerant persister cells promotes castration-resistant prostate cancer, and disruption of its interaction with NRF2 restores drug sensitivity [PMID:38115765, PMID:39168191]."},"prefetch_data":{"uniprot":{"accession":"P30044","full_name":"Peroxiredoxin-5, mitochondrial","aliases":["Alu corepressor 1","Antioxidant enzyme B166","AOEB166","Liver tissue 2D-page spot 71B","PLP","Peroxiredoxin V","Prx-V","Peroxisomal antioxidant enzyme","TPx type VI","Thioredoxin peroxidase PMP20","Thioredoxin-dependent peroxiredoxin 5"],"length_aa":214,"mass_kda":22.1,"function":"Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively. Plays a role in cell protection against oxidative stress by detoxifying peroxides and as sensor of hydrogen peroxide-mediated signaling events","subcellular_location":"Cytoplasm; Peroxisome matrix","url":"https://www.uniprot.org/uniprotkb/P30044/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRDX5","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"SAR1B","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/PRDX5","total_profiled":1310},"omim":[{"mim_id":"619862","title":"SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 32; SCAR32","url":"https://www.omim.org/entry/619862"},{"mim_id":"618756","title":"ABHYDROLASE DOMAIN-CONTAINING PROTEIN 10, DEPALMITOYLASE; ABHD10","url":"https://www.omim.org/entry/618756"},{"mim_id":"606583","title":"PEROXIREDOXIN 5; PRDX5","url":"https://www.omim.org/entry/606583"},{"mim_id":"604769","title":"PEROXIREDOXIN 3; PRDX3","url":"https://www.omim.org/entry/604769"},{"mim_id":"601244","title":"GUANYLATE CYCLASE 1, SOLUBLE, ALPHA-2; GUCY1A2","url":"https://www.omim.org/entry/601244"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Mitochondria","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"choroid plexus","ntpm":1322.0}],"url":"https://www.proteinatlas.org/search/PRDX5"},"hgnc":{"alias_symbol":["ACR1","AOEB166","MGC142285","PRXV","PMP20","B166","PRDX6","PLP","SBBI10","MGC117264","MGC142283"],"prev_symbol":[]},"alphafold":{"accession":"P30044","domains":[{"cath_id":"3.40.30.10","chopping":"63-214","consensus_level":"high","plddt":98.2612,"start":63,"end":214}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P30044","model_url":"https://alphafold.ebi.ac.uk/files/AF-P30044-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P30044-F1-predicted_aligned_error_v6.png","plddt_mean":85.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRDX5","jax_strain_url":"https://www.jax.org/strain/search?query=PRDX5"},"sequence":{"accession":"P30044","fasta_url":"https://rest.uniprot.org/uniprotkb/P30044.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P30044/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P30044"}},"corpus_meta":[{"pmid":"10521424","id":"PMC_10521424","title":"Cloning and characterization of AOEB166, a novel mammalian antioxidant enzyme of the peroxiredoxin family.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10521424","citation_count":209,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9234670","id":"PMC_9234670","title":"Isolation of three contiguous genes, ACR1, ACR2 and ACR3, involved in resistance to arsenic compounds in the yeast Saccharomyces cerevisiae.","date":"1997","source":"Yeast (Chichester, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9234670","citation_count":156,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9395087","id":"PMC_9395087","title":"Identification of the yeast ACR1 gene product as a succinate-fumarate transporter essential for growth on ethanol or acetate.","date":"1997","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9395087","citation_count":125,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10514471","id":"PMC_10514471","title":"Characterization of human and murine PMP20 peroxisomal proteins that exhibit antioxidant activity in vitro.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10514471","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16046399","id":"PMC_16046399","title":"Dodecameric structure of the small heat shock protein Acr1 from Mycobacterium tuberculosis.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16046399","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1448073","id":"PMC_1448073","title":"ACR1, a yeast ATF/CREB repressor.","date":"1992","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1448073","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18694816","id":"PMC_18694816","title":"Absence of the peroxiredoxin Pmp20 causes peroxisomal protein leakage and necrotic cell death.","date":"2008","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18694816","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24218502","id":"PMC_24218502","title":"Latency-associated protein Acr1 impairs dendritic cell maturation and functionality: a possible mechanism of immune evasion by Mycobacterium tuberculosis.","date":"2013","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/24218502","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7908717","id":"PMC_7908717","title":"ACR1, a gene encoding a protein related to mitochondrial carriers, is essential for acetyl-CoA synthetase activity in Saccharomyces cerevisiae.","date":"1994","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/7908717","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31899687","id":"PMC_31899687","title":"PRDX5 as a novel binding partner in Nrf2-mediated NSCLC progression under oxidative stress.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31899687","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26686819","id":"PMC_26686819","title":"Proteomonas sulcata ACR1: A Fast Anion Channelrhodopsin.","date":"2016","source":"Photochemistry and photobiology","url":"https://pubmed.ncbi.nlm.nih.gov/26686819","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32339330","id":"PMC_32339330","title":"PCAT6 mediates cellular biological functions in gastrointestinal stromal tumor via upregulation of PRDX5 and activation of Wnt pathway.","date":"2020","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/32339330","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25025339","id":"PMC_25025339","title":"Comparing binding modes of analogous fragments using NMR in fragment-based drug design: application to PRDX5.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25025339","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33416106","id":"PMC_33416106","title":"ROS‑mediated hypomethylation of PRDX5 promotes STAT3 binding and activates the Nrf2 signaling pathway in NSCLC.","date":"2020","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33416106","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20451279","id":"PMC_20451279","title":"Comparative proteome profile during the early period of small-for-size liver transplantation in rats revealed the protective role of Prdx5.","date":"2010","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/20451279","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28611779","id":"PMC_28611779","title":"Diametric Role of the Latency-Associated Protein Acr1 of Mycobacterium tuberculosis in Modulating the Functionality of Pre- and Post-maturational Stages of Dendritic Cells.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28611779","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38115765","id":"PMC_38115765","title":"Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38115765","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36067023","id":"PMC_36067023","title":"Prdx5 regulates DNA damage response through autophagy-dependent Sirt2-p53 axis.","date":"2023","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36067023","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37305326","id":"PMC_37305326","title":"The synergistic effects of PRDX5 and Nrf2 on lung cancer progression and drug resistance under oxidative stress in the zebrafish models.","date":"2023","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/37305326","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37996809","id":"PMC_37996809","title":"Maresin1 ameliorates MSU crystal-induced inflammation by upregulating Prdx5 expression.","date":"2023","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/37996809","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39955823","id":"PMC_39955823","title":"Chaihuang Yishen Granule ameliorates mitochondrial homeostasis by upregulating PRDX5/TFAM axis to inhibit renal fibrosis in CKD.","date":"2025","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39955823","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10094465","id":"PMC_10094465","title":"Multiple regulatory elements control the expression of the yeast ACR1 gene.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10094465","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16703514","id":"PMC_16703514","title":"A multidrug-resistant, acr1-deficient clinical isolate of Mycobacterium tuberculosis is unimpaired for replication in macrophages.","date":"2006","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/16703514","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12500669","id":"PMC_12500669","title":"[The BCL-xL and ACR-1 genes promote differentiation and reduce apoptosis in muscle fibers of mdx mice].","date":"2002","source":"Genetika","url":"https://pubmed.ncbi.nlm.nih.gov/12500669","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30395609","id":"PMC_30395609","title":"Mycobacterium tuberculosis host cell interaction: Role of latency associated protein Acr-1 in differential modulation of macrophages.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30395609","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39780184","id":"PMC_39780184","title":"PRDX5 and PRDX6 translocation and oligomerization in bull sperm: a response to cryopreservation-induced oxidative stress.","date":"2025","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/39780184","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38880456","id":"PMC_38880456","title":"A novel strategy to elicit enduring anti-morphine immunity and relief from addiction by targeting Acr1 protein nano vaccine through TLR-2 to dendritic cells.","date":"2024","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/38880456","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35985565","id":"PMC_35985565","title":"Molecular cloning, prokaryotic expression and the anti-inflammatory activity of porcine PRDX5.","date":"2022","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35985565","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40015209","id":"PMC_40015209","title":"Prdx5 regulates macrophage polarization by modulating the TLR4/NF-κB pathway to promote apoptosis in chronic prostatitis.","date":"2025","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40015209","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39900986","id":"PMC_39900986","title":"Elevated serum levels of GPX4, NDUFS4, PRDX5, and TXNRD2 as predictive biomarkers for castration resistance in prostate cancer patients: an exploratory study.","date":"2025","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39900986","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41147088","id":"PMC_41147088","title":"PRDX5 Regulates Mitochondrial Function and Nuclear Spreading in Myogenesis and Acts With PRDX3 to Delay Muscle Aging.","date":"2025","source":"Journal of cachexia, sarcopenia and muscle","url":"https://pubmed.ncbi.nlm.nih.gov/41147088","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40122834","id":"PMC_40122834","title":"Single-cell sequencing combined with urinary multi-omics analysis reveals that the non-invasive biomarker PRDX5 regulates bladder cancer progression through ferroptosis signaling.","date":"2025","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40122834","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40654183","id":"PMC_40654183","title":"Salvianolic Acid B Attenuates Ferroptosis in Acute Kidney Injury by Targeting PRDX5.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/40654183","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39168191","id":"PMC_39168191","title":"Prebiotic stachyose inhibits PRDX5 activity and castration-resistant prostate cancer development.","date":"2024","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/39168191","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37443747","id":"PMC_37443747","title":"Prdx5 in the Regulation of Tuberous Sclerosis Complex Mutation-Induced Signaling Mechanisms.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37443747","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40818507","id":"PMC_40818507","title":"Activation of SIRT3 / PRDX5 signaling inhibits apoptosis after acute spinal cord injury in mice.","date":"2025","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/40818507","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39571926","id":"PMC_39571926","title":"First report of Peroxiredoxin-5 (PRDX5) in starry flounder (Platichthys stellatus): Molecular features and expression analysis.","date":"2024","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39571926","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40798978","id":"PMC_40798978","title":"F18 Promiscuous Epitope of Acr1 Protein of Mycobacterium tuberculosis Induces the Secretion of IL-10 and Tregs but Not IL-6.","date":"2025","source":"Protein and peptide letters","url":"https://pubmed.ncbi.nlm.nih.gov/40798978","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41359162","id":"PMC_41359162","title":"IER3 drives the transition from sepsis-associated AKI to CKD by suppressing the mitochondrial translocation of PRDX5.","date":"2025","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/41359162","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40775543","id":"PMC_40775543","title":"Ethyl β-carboline-3-carboxylate targets PRDX5/c-Jun axis for novel therapeutic strategy against cervical cancer.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40775543","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41111357","id":"PMC_41111357","title":"Mycobacterium tuberculosis Acr1 Protein Mitigates Experimental Autoimmune Encephalomyelitis Symptoms by Generating Myeloid-Derived Suppressor Cells and Regulatory T Cells.","date":"2025","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41111357","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41760234","id":"PMC_41760234","title":"CD133+ Lung Cancer Stem-like Cells Resist Plasma-activated Medium Through PRDX5-mediated Antioxidant Defense.","date":"2026","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/41760234","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41740330","id":"PMC_41740330","title":"Acetylation of PRDX5 aggravates the oxidative stress and apoptosis of retinal neurons induced by ischemia-reperfusion.","date":"2026","source":"Tissue & cell","url":"https://pubmed.ncbi.nlm.nih.gov/41740330","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27588091","id":"PMC_27588091","title":"Association between ACR1 gene product expression and cardiomyopathy in children.","date":"2016","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27588091","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21102463","id":"PMC_21102463","title":"Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21102463","citation_count":2036,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12517450","id":"PMC_12517450","title":"Structure, mechanism and regulation of peroxiredoxins.","date":"2003","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12517450","citation_count":1912,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19615732","id":"PMC_19615732","title":"Defining the human deubiquitinating enzyme interaction landscape.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19615732","citation_count":1282,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20596022","id":"PMC_20596022","title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20596022","citation_count":621,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10751410","id":"PMC_10751410","title":"Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10751410","citation_count":385,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32838362","id":"PMC_32838362","title":"Virus-Host Interactome and Proteomic Survey Reveal Potential Virulence Factors Influencing SARS-CoV-2 Pathogenesis.","date":"2020","source":"Med (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32838362","citation_count":291,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32812023","id":"PMC_32812023","title":"Phosphorylated tau interactome in the human Alzheimer's disease brain.","date":"2020","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32812023","citation_count":290,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21654808","id":"PMC_21654808","title":"A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21654808","citation_count":269,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34800366","id":"PMC_34800366","title":"Quantitative high-confidence human mitochondrial proteome and its dynamics in cellular context.","date":"2021","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34800366","citation_count":239,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19199708","id":"PMC_19199708","title":"Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT).","date":"2009","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/19199708","citation_count":237,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20977338","id":"PMC_20977338","title":"Peroxiredoxin 5: structure, mechanism, and function of the mammalian atypical 2-Cys peroxiredoxin.","date":"2011","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/20977338","citation_count":208,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11518528","id":"PMC_11518528","title":"Crystal structure of human peroxiredoxin 5, a novel type of mammalian peroxiredoxin at 1.5 A resolution.","date":"2001","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11518528","citation_count":196,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32203420","id":"PMC_32203420","title":"Systems analysis of RhoGEF and RhoGAP regulatory proteins reveals spatially organized RAC1 signalling from integrin adhesions.","date":"2020","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32203420","citation_count":194,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30833792","id":"PMC_30833792","title":"A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape.","date":"2019","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30833792","citation_count":159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32416067","id":"PMC_32416067","title":"Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.","date":"2020","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/32416067","citation_count":159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15280035","id":"PMC_15280035","title":"Human peroxiredoxin 5 is a peroxynitrite reductase.","date":"2004","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15280035","citation_count":155,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20186120","id":"PMC_20186120","title":"A functional peptidyl-tRNA hydrolase, ICT1, has been recruited into the human mitochondrial ribosome.","date":"2010","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/20186120","citation_count":153,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10679306","id":"PMC_10679306","title":"Mouse peroxiredoxin V is a thioredoxin peroxidase that inhibits p53-induced apoptosis.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10679306","citation_count":144,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23533145","id":"PMC_23533145","title":"In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.","date":"2013","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/23533145","citation_count":138,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":24088,"output_tokens":4179,"usd":0.067475},"stage2":{"model":"claude-opus-4-6","input_tokens":7614,"output_tokens":2996,"usd":0.169455},"total_usd":0.557359,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":36684,"output_tokens":6776,"usd":0.105846},"round2_rules_fired":"R2,R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":10716,"output_tokens":3579,"usd":0.214583}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"PRDX5 (AOEB166) is a mammalian peroxiredoxin with peroxidase activity; recombinant protein expressed in E. coli exhibits peroxidase activity and antioxidant activity comparable to catalase in the glutamine synthetase protection assay. The protein is targeted to mitochondria and peroxisomes, demonstrated by GFP fusion protein sorting in HepG2 cells.\",\n      \"method\": \"In vitro peroxidase assay with recombinant protein, glutamine synthetase protection assay, GFP fusion protein live-cell imaging in HepG2 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted enzymatic activity in vitro plus direct subcellular localization by live imaging, foundational paper with 209 citations\",\n      \"pmids\": [\"10521424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Human PMP20 (PRDX5) localizes to peroxisomes via its C-terminal PTS1 signal (SQL tripeptide), directly binds the peroxisomal targeting signal receptor PEX5, and exhibits thiol-specific antioxidant and thiol-peroxidase (H2O2-removing) activity in vitro. Mutagenesis of the SQL sequence abolished PEX5 binding.\",\n      \"method\": \"Subcellular fractionation, double-label immunofluorescence with peroxisomal marker thiolase, direct binding assay with PEX5, C-terminal mutagenesis, in vitro thiol-peroxidase assay, glutamine synthetase protection assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution of peroxidase activity, mutagenesis of targeting signal, and direct binding to receptor, replicated across human and mouse proteins\",\n      \"pmids\": [\"10514471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRDX5 physically interacts with Nrf2 in H2O2-stimulated NSCLC cells, and this interaction promotes expression of NQO1 protein.\",\n      \"method\": \"Co-immunoprecipitation in NSCLC cells under oxidative stress, Western blotting for NQO1\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP with functional readout (NQO1 upregulation), single lab\",\n      \"pmids\": [\"31899687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRDX5 regulates the DNA damage response (DDR) pathway: Prdx5 knockdown induces γ-H2AX and 53BP1 foci; Prdx5 modulates DDR through Plk1-mediated ATM phosphorylation and downstream Chek1/Chek2 activation. Prdx5 also controls p53 acetylation at lysine 382 via the deacetylase Sirt2, which was identified as a novel p53-K382 deacetylase acting in a Prdx5-dependent manner. Additionally, Prdx5 induces autophagy to recycle DDR molecules.\",\n      \"method\": \"siRNA knockdown, Western blotting for γ-H2AX/53BP1/p53-AcK382, epistasis experiments with Sirt2, autophagy assays, exogenous Prdx5 expression in Pkd1 mutant cells\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KD with defined molecular phenotypes and pathway placement via epistasis, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"36067023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRDX5 and Nrf2 form a complex confirmed by Co-immunoprecipitation and Western blotting; the complex is enhanced under oxidative stress (H2O2 treatment) and is positively associated with proliferation and drug resistance in NSCLC.\",\n      \"method\": \"Co-immunoprecipitation, Western blotting, immunohistochemistry, zebrafish in vivo models\",\n      \"journal\": \"Oncology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 + Strong — multiple papers confirming PRDX5-Nrf2 interaction, replicated from prior work\",\n      \"pmids\": [\"37305326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PRDX5 interacts with TFAM (mitochondrial transcription factor A); PRDX5 overexpression activates TFAM and maintains mitochondrial homeostasis, while TFAM knockdown reverses the mitochondrial and fibrotic improvements conferred by PRDX5 overexpression.\",\n      \"method\": \"Protein binding assays (co-immunoprecipitation/pulldown), overexpression and knockdown experiments, mitochondrial function assays in renal tubular cells\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — protein interaction with TFAM demonstrated by binding assay, epistasis via TFAM KD rescuing PRDX5 gain-of-function, single lab\",\n      \"pmids\": [\"39955823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"IER3 interacts with the mitochondrial protease PARL and inhibits its shear activity, thereby blocking mitochondrial translocation of cytoplasmic PRDX5 and reducing mitochondrial antioxidant capacity; PRDX5 inhibition blocked the effects of IER3 knockout on renal tubular cell senescence.\",\n      \"method\": \"RNA-seq of IER3-/- renal tissues, PRDX5 inhibition epistasis, co-immunoprecipitation of IER3 with PARL, functional assays for mitochondrial PRDX5 levels\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (IER3 KO + PRDX5 inhibition), co-IP for IER3/PARL interaction, mechanistic link to PRDX5 mitochondrial translocation\",\n      \"pmids\": [\"41359162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SIRT3 deacetylase acts upstream of PRDX5 in neurons; transcriptome analysis of Sirt3-/- mice identified PRDX5 as a direct downstream effector; SIRT3 and PRDX5 colocalize in anterior horn neurons, and PRDX5 silencing partially abrogated SIRT3-mediated neuroprotection after spinal cord injury.\",\n      \"method\": \"Transcriptome analysis of Sirt3-/- mouse renal tissues, co-localization by immunofluorescence, genetic epistasis via PRDX5 silencing in SIRT3-activated context, in vivo spinal cord injury model\",\n      \"journal\": \"Brain research bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis (PRDX5 KD reverting SIRT3 effect) plus transcriptomics-guided identification and co-localization, single lab\",\n      \"pmids\": [\"40818507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PRDX5 undergoes acetylation, and this modification inhibits its antioxidant and anti-apoptotic function; OGD/R injury increases PRDX5 acetylation in retinal neurons, and deacetylation (promoted by NRC treatment) reduces ROS and apoptosis, while acetylation enhancement (NAM treatment) abolishes the protective effect of PRDX5 overexpression.\",\n      \"method\": \"Western blotting for acetylation status, pharmacological modulation of acetylation (NAM/NRC), overexpression and knockdown in OGD/R model, ROS assay, apoptosis assay, in vivo retinal I/R mouse model\",\n      \"journal\": \"Tissue & cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct detection of PTM with pharmacological manipulation linking acetylation to loss of PRDX5 function, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"41740330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Under cryopreservation-induced oxidative stress, PRDX5 undergoes intracellular translocation and forms high-molecular-weight oligomers in bull sperm, potentially shifting from peroxidase to chaperone activity; PRDX5 interaction with TLR4 is implicated in its intracellular transport.\",\n      \"method\": \"Imaging Flow Cytometry, native and denaturing PAGE, Western blotting for oligomers, co-detection with TLR4\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP/co-detection with TLR4, oligomerization detected but chaperone shift is inferred\",\n      \"pmids\": [\"39780184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PRDX5 is localized to mitochondria in myotubes; Prdx5 deficiency impairs nuclear spreading (myonuclear positioning) during myogenesis and reduces mitochondrial ATP production; the effect on nuclear positioning is linked to decreased transcriptional expression of Rhot1 and Trak1 (mitochondrial transport regulators), and knockdown of either rescues the clustered-nuclei phenotype.\",\n      \"method\": \"Confocal and super-resolution SIM microscopy, Seahorse OCR assay, RT-qPCR for Rhot1/Trak1, siRNA knockdown epistasis in myotubes, Prdx5-/- mouse model with in vivo grip strength and treadmill performance\",\n      \"journal\": \"Journal of cachexia, sarcopenia and muscle\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic KO with defined cellular phenotype, epistasis with Rhot1/Trak1 knockdown, multiple orthogonal methods including live imaging and mitochondrial function assay\",\n      \"pmids\": [\"41147088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PRDX5 promotes M1 macrophage polarization via the TLR4/NF-κB pathway; PRDX5 expression in macrophages is regulated in a ROS-dependent manner, and silencing PRDX5 suppressed M1 polarization and reduced apoptosis of prostate epithelial cells.\",\n      \"method\": \"Western blotting, RT-qPCR, immunofluorescence, flow cytometry, siRNA knockdown, NF-κB pathway readout, co-culture assays\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KD with defined pathway placement via TLR4/NF-κB, multiple methods, single lab\",\n      \"pmids\": [\"40015209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Stachyose inhibits PRDX5 enzymatic activity and disrupts the PRDX5-NRF2 protein-protein interaction, leading to decreased NQO1 and accumulation of quinone radicals; PRDX5-NRF2 interaction validated as a pharmacologically targetable mechanism in castration-resistant prostate cancer.\",\n      \"method\": \"PRDX5 enzyme activity assay, co-immunoprecipitation for PRDX5-NRF2 interaction, NQO1 Western blotting, in vivo CRPC mouse model\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct enzymatic inhibition assay plus Co-IP for protein interaction disruption, single lab\",\n      \"pmids\": [\"39168191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Salvianolic acid B binds directly to PRDX5 (confirmed by DARTS, CETSA, and molecular docking) and enhances its redox activity, which potentiates SLC7A11 and GPX4-mediated inhibition of ferroptosis in renal tubular cells; silencing PRDX5 abolished SAB's protective effect.\",\n      \"method\": \"Drug affinity responsive target stability (DARTS), cellular thermal shift assay (CETSA), molecular docking, siRNA knockdown epistasis, in vivo AKI mouse models\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct target engagement confirmed by three orthogonal biophysical/biochemical methods (DARTS, CETSA, docking), plus epistasis confirming on-target mechanism\",\n      \"pmids\": [\"40654183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Porcine PRDX5's anti-inflammatory activity depends on its peroxidase activity; recombinant pPRDX5 inhibited TNF-α- and PRRSV-induced inflammatory responses in macrophages, and this regulation was abolished when peroxidase activity was disrupted.\",\n      \"method\": \"Recombinant protein treatment, siRNA knockdown, peroxidase activity-deficient mutant, Western blotting for inflammatory markers\",\n      \"journal\": \"Developmental and comparative immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — peroxidase activity mutant linking catalytic activity to anti-inflammatory function, single lab\",\n      \"pmids\": [\"35985565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NMR-based fragment binding studies (STD and 15N-HSQC) identified the binding modes of small-molecule fragments to the active site of human PRDX5, validating the protein's active site as a druggable target.\",\n      \"method\": \"NMR (STD, 15N-HSQC), chemical shift perturbation mapping\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — structural NMR with functional site mapping, single lab study\",\n      \"pmids\": [\"25025339\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRDX5 is a mitochondrial and peroxisomal thiol-dependent peroxidase (atypical 2-Cys peroxiredoxin) that detoxifies H2O2 and alkyl hydroperoxides using its catalytic Cys residues; it is imported into peroxisomes via the PTS1 receptor PEX5, localizes to mitochondria where it regulates mitochondrial function and nuclear positioning during myogenesis (via transcriptional control of Rhot1/Trak1), physically interacts with Nrf2 (enhancing NQO1 expression), TFAM, and TLR4, modulates the DNA damage response through an ATM/Plk1/Sirt2/p53 axis, undergoes acetylation that inhibits its antioxidant activity, and acts downstream of SIRT3 and upstream of mitochondrial translocation control by IER3/PARL, collectively placing PRDX5 as a redox-sensing hub that couples ROS detoxification to transcriptional, inflammatory, and DNA damage signaling pathways.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"PRDX5 (originally named AOEB166) was identified as a novel mammalian peroxiredoxin with peroxidase activity. Recombinant AOEB166 expressed in E. coli exhibits peroxidase activity and antioxidant activity comparable to catalase. The protein contains both mitochondrial and peroxisomal targeting sequences, and GFP-fusion protein expressed in HepG2 cells is sorted to both organelles.\",\n      \"method\": \"Recombinant protein expression in E. coli, glutamine synthetase protection assay, GFP fusion subcellular localization in HepG2 cells, mRNA distribution analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay plus direct subcellular localization experiment\",\n      \"pmids\": [\"10521424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Human PMP20 (PRDX5 ortholog) localizes to peroxisomes via a C-terminal PTS1 signal (SQL tripeptide) that binds the peroxisomal targeting signal receptor HsPEX5; mutagenesis of the SQL sequence abolishes binding to HsPEX5. HsPMP20 exhibits thiol-specific antioxidant activity (inhibiting glutamine synthetase inactivation in thiol-dependent oxidation system) and thiol-peroxidase activity removing H2O2.\",\n      \"method\": \"Mutagenesis analysis, direct binding assay to HsPEX5, subcellular fractionation, double-staining immunofluorescence, glutamine synthetase protection assay, thiol-peroxidase activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution of peroxisomal import mechanism with mutagenesis validation plus in vitro enzymatic assays\",\n      \"pmids\": [\"10514471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PrxV (PRDX5) forms an intramolecular disulfide as a reaction intermediate during peroxide reduction, distinguishing it from other peroxiredoxins that form intermolecular disulfides or sulfenic acid intermediates. Cys48 is the peroxidatic site oxidized by peroxides, and oxidized Cys48 reacts with Cys152 to form an intramolecular disulfide. The disulfide is reduced by thioredoxin but not by glutaredoxin or glutathione. PRDX5 is localized to cytosol, mitochondria, and peroxisomes. Overexpression of wild-type but not Cys48 mutant inhibited H2O2 accumulation and c-Jun N-terminal kinase activation induced by TNF-alpha in NIH 3T3 cells.\",\n      \"method\": \"Site-directed mutagenesis of each Cys residue, thioredoxin-dependent peroxidase activity assay, immunoblot analysis of tissue distribution, subcellular localization by fractionation, transient overexpression with H2O2 and JNK activation readouts\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay with mutagenesis of catalytic residues plus functional cellular readout\",\n      \"pmids\": [\"10751410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Mouse peroxiredoxin V (PRDX5) is a thioredoxin peroxidase that inhibits p53-induced apoptosis. Overexpression of Prx-V prevented p53-dependent generation of reactive oxygen species and inhibited p53-induced apoptosis in mammalian cells.\",\n      \"method\": \"Overexpression in mammalian cells, ROS measurement, apoptosis assay, thioredoxin peroxidase activity assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean overexpression with defined cellular phenotype (ROS suppression, apoptosis inhibition) but single lab, limited mechanistic detail\",\n      \"pmids\": [\"10679306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The 1.5 Å crystal structure of human PRDX5 in reduced form reveals a thioredoxin-like domain. Unlike other mammalian peroxiredoxins, PRDX5 does not form a homodimer. In the reduced form, the catalytic Cys47 and Cys151 are 13.8 Å apart, indicating a conformational change is required to form the intramolecular disulfide upon oxidation. A benzoate ion was found near the active-site pocket.\",\n      \"method\": \"X-ray crystallography at 1.5 Å resolution\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure revealing catalytic mechanism and unique structural features\",\n      \"pmids\": [\"11518528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PRDX5 is classified as the atypical 2-Cys peroxiredoxin: it uses an active-site cysteine (peroxidatic Cys) oxidized to sulfenic acid by peroxide substrate, then forms an intramolecular disulfide with the resolving Cys, recycled by thioredoxin. This mechanism is distinct from typical 2-Cys Prxs (intermolecular disulfide) and 1-Cys Prxs.\",\n      \"method\": \"Biochemical analysis and crystal structure review; mechanistic classification based on structural and mutational data\",\n      \"journal\": \"Trends in biochemical sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — review synthesizing crystal structure and mutagenesis data, widely replicated mechanistic framework\",\n      \"pmids\": [\"12517450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Human PRDX5 is a peroxynitrite reductase. The nucleophilic attack on the O-O bond of peroxynitrite is performed by the N-terminal peroxidatic Cys47. Using pulse radiolysis, the rate constant for peroxynitrite reduction was measured at (7±3)×10^7 M⁻¹s⁻¹, among the highest reported for any peroxynitrite reductase.\",\n      \"method\": \"Cysteine mutant analysis, pulse radiolysis to determine rate constant\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — pulse radiolysis (direct kinetic measurement) combined with mutagenesis identifying catalytic residue\",\n      \"pmids\": [\"15280035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PRDX5 is the unique atypical 2-Cys peroxiredoxin in mammals, localized to mitochondria, peroxisomes, cytosol, and nucleus. It reduces alkyl hydroperoxides and peroxynitrite using cytosolic or mitochondrial thioredoxins with rate constants of 10^6–10^7 M⁻¹s⁻¹, while reduction of H2O2 is more modest (~10^5 M⁻¹s⁻¹). Overexpression in different subcellular compartments protects cells from nitro-oxidative stress, while gene silencing increases vulnerability.\",\n      \"method\": \"Biochemical kinetic assays, subcellular fractionation, overexpression and knockdown with cell viability readouts (comprehensive review of accumulated experimental data)\",\n      \"journal\": \"Antioxidants & redox signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — synthesis of multiple independent in vitro and cellular experiments across multiple labs\",\n      \"pmids\": [\"20977338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Prdx5 overexpression via adenoviral vector in small-for-size liver grafts during transplantation attenuated graft injury and increased recipient survival, demonstrating a protective role of Prdx5 in ischemia-reperfusion injury in vivo.\",\n      \"method\": \"Adenoviral overexpression in rat liver transplantation model, proteomics (2D-PAGE/MALDI-TOF), Western blotting, immunohistochemistry, survival analysis\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gain-of-function with defined phenotype (reduced injury, increased survival) but limited mechanistic pathway placement\",\n      \"pmids\": [\"20451279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRDX5 was identified as a novel binding partner of Nrf2 in NSCLC cells under H2O2-stimulated oxidative stress. The PRDX5–Nrf2 interaction promotes expression of NQO1 in NSCLC cells. Knockdown of both Nrf2 and PRDX5 significantly reduced tumor growth in animal models.\",\n      \"method\": \"Co-immunoprecipitation, Western blotting, shRNA knockdown, animal tumor growth assays\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP demonstrating interaction plus in vivo functional validation, single lab\",\n      \"pmids\": [\"31899687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ROS-induced hypomethylation of the PRDX5 promoter enhances STAT3 binding at two specific sites (−444 to −434 bp and −1417 to −1407 bp), increasing PRDX5 expression. STAT3 knockdown decreased PRDX5 protein levels while STAT3 overexpression increased them. PRDX5 overexpression activated the Nrf2 signaling pathway and promoted EMT (decreased E-cadherin, increased vimentin) in NSCLC cells under oxidative stress.\",\n      \"method\": \"Bisulfite sequencing PCR, ChIP assay, luciferase detection assay, STAT3 knockdown/overexpression, siRNA and pcDNA3.1 transfection with Western blotting\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirms direct STAT3 binding at PRDX5 promoter; multiple orthogonal methods in single lab\",\n      \"pmids\": [\"33416106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRDX5 regulates the DNA damage response (DDR) through multiple mechanisms: (1) Plk1-mediated phosphorylation of ATM kinase triggering downstream Chek1/Chek2; (2) regulation of p53 acetylation at lysine 382 via Sirt2, which was identified as a novel deacetylase of p53 at K382 in a Prdx5-dependent manner; (3) induction of autophagy that recycles DDR molecules. Prdx5 knockdown induced γ-H2AX and 53BP1 (DNA damage markers), while exogenous Prdx5 decreased DNA damage and ATM activation in Pkd1 mutant renal epithelial cells.\",\n      \"method\": \"siRNA knockdown, γ-H2AX and 53BP1 immunofluorescence, Western blotting for phospho-ATM/Chek1/Chek2, p53 acetylation assays, autophagy assays, exogenous PRDX5 expression in Pkd1 mutant cells\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods establishing pathway position (ATM/p53/Sirt2), single lab\",\n      \"pmids\": [\"36067023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRDX5 promotes AR inhibitor resistance and castration-resistant prostate cancer (CRPC) development. The thioredoxin/peroxiredoxin pathway is upregulated in drug-tolerant persister (DTP) cells. Inhibition of PRDX5 suppresses DTP cell proliferation in culture and dampens CRPC development in animal models.\",\n      \"method\": \"Cell culture proliferation assays, animal models of CRPC, pathway analysis, PRDX5 inhibition\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined cellular and in vivo phenotype, supported by patient data\",\n      \"pmids\": [\"38115765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRDX5 and Nrf2 form a protein complex that is enhanced by oxidative stress (H2O2 treatment). The PRDX5–Nrf2 complex synergistically promotes NSCLC cell proliferation and drug resistance in zebrafish models.\",\n      \"method\": \"Co-immunoprecipitation, Western blotting, immunohistochemistry, zebrafish xenograft models\",\n      \"journal\": \"Oncology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP confirms complex; zebrafish functional validation; single lab\",\n      \"pmids\": [\"37305326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"During cryopreservation-induced oxidative stress in bull sperm, PRDX5 translocates intracellularly and forms high molecular weight oligomers that may shift from peroxidase to chaperone roles. PRDX5 interaction with TLR4 may be key to its intracellular transport. PRDX5 is also found in exosomal vesicles, suggesting a potential transport mechanism.\",\n      \"method\": \"Imaging Flow Cytometry, native PAGE and SDS-PAGE techniques (various), ROS/NO measurement, mitochondrial potential assay, DNA fragmentation assay\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, translocation and oligomerization observed but mechanistic link to TLR4 is correlative\",\n      \"pmids\": [\"39780184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PRDX5 regulates mitochondrial function and myonuclear positioning during myogenesis. Prdx5-/- myotubes exhibit impaired nuclear spreading (clustered nuclei) and reduced mitochondrial ATP production. PRDX5 facilitates mitochondrial transport and nuclear positioning at least in part through transcriptional regulation of Rhot1 and Trak1 (key mitochondrial transport regulators). Double knockout of Prdx3 and Prdx5 accelerates muscle aging with increased mitochondrial H2O2 production, upregulating E3 ligases Atrogin1 and MuRF1.\",\n      \"method\": \"Prdx5-/- and Prdx3-/-;Prdx5-/- mouse models, confocal and super-resolution lattice SIM microscopy, Seahorse OCR assays, Rhot1/Trak1 knockdown, grip strength, treadmill performance, histology\",\n      \"journal\": \"Journal of cachexia, sarcopenia and muscle\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with multiple orthogonal methods, mechanistic linkage to mitochondrial transport via Rhot1/Trak1 validated by independent knockdown\",\n      \"pmids\": [\"41147088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"IER3 inhibits mitochondrial translocation of PRDX5 by interacting with the presenilin-associated rhomboid-like protease (Parl) and reducing its shear activity, thereby preventing cleavage and mitochondrial import of cytoplasmic PRDX5. Reduced mitochondrial PRDX5 impairs antioxidant capacity, causes oxidative mitochondrial damage and abnormal perinuclear mitochondrial clustering, promoting RTEC stress-induced senescence and AKI-to-CKD transition.\",\n      \"method\": \"IER3 knockout mice, RNA-seq, PRDX5 inhibition rescue experiments, co-immunoprecipitation (IER3–Parl interaction), mitochondrial fractionation, senescence assays\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus Co-IP identifying IER3–Parl–PRDX5 axis; single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"41359162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PRDX5 interacts with TFAM; PRDX5 overexpression enhances TFAM activation to counteract ROS-induced mitochondrial damage and restore mitochondrial homeostasis in renal tubular cells. TFAM knockdown reverses the mitochondrial functional improvements achieved through PRDX5 overexpression.\",\n      \"method\": \"Protein binding assays (PRDX5–TFAM interaction), ultrasound microbubble-mediated in situ PRDX5 overexpression, PRDX5 knockdown, TFAM knockdown, mtDNA leakage assay, mitochondrial function assays in CKD models\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — protein interaction identified but mechanistic detail of PRDX5–TFAM interaction limited; single lab\",\n      \"pmids\": [\"39955823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SIRT3 activates PRDX5 as its direct downstream effector in neurons; SIRT3 and PRDX5 co-localize in the anterior horn spinal cord neurons. Genetic silencing of PRDX5 partially attenuated SIRT3-mediated neuroprotection against apoptosis after spinal cord injury, placing PRDX5 downstream of SIRT3 in a neuroprotective axis.\",\n      \"method\": \"Transcriptome analysis of Sirt3-/- mice, SIRT3 agonist (honokiol) treatment, PRDX5 siRNA knockdown, immunofluorescence co-localization, neurological functional assessments in SCI mouse model\",\n      \"journal\": \"Brain research bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established by transcriptomics + genetic silencing rescue experiment; single lab\",\n      \"pmids\": [\"40818507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Prdx5 promotes M1 macrophage polarization and apoptosis of prostate epithelial cells via the TLR4/NF-κB signaling pathway in an ROS-dependent manner. Prdx5 silencing suppressed M1 polarization, reduced epithelial cell apoptosis, and mitigated experimental autoimmune prostatitis. Prdx5 expression in macrophages is regulated in an ROS-dependent manner.\",\n      \"method\": \"Prdx5 siRNA silencing, Western blotting, RT-qPCR, flow cytometry, cell co-culture, immunofluorescence staining, EAP mouse model\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined pathway (TLR4/NF-κB) and cellular phenotype (M1 polarization), single lab\",\n      \"pmids\": [\"40015209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Acetylation of PRDX5 inhibits its antioxidant and anti-apoptotic functions. OGD/R increased PRDX5 acetylation in retinal neurons; NAM treatment that increased acetylation elevated ROS and apoptosis, while NRC treatment that reduced acetylation decreased ROS and apoptosis. Inhibiting deacetylation abolished the protective effect of PRDX5 overexpression, demonstrating that acetylation status directly controls PRDX5 activity.\",\n      \"method\": \"OGD/R model in R28 cells, aHIOP mouse model, nicotinamide and NRC pharmacological modulation of acetylation, PRDX5 knockdown and overexpression, ROS measurement, mitochondrial membrane potential, TUNEL/PI staining, LDH release\",\n      \"journal\": \"Tissue & cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological modulation of acetylation with functional readout; identity of acetylase/deacetylase not fully established; single lab\",\n      \"pmids\": [\"41740330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Salvianolic acid B (SAB) binds directly to PRDX5 (confirmed by DARTS, CETSA, and molecular docking) and enhances its redox activity, which in turn potentiates SLC7A11 and GPX4 inhibitory effects on ferroptosis. PRDX5 silencing partially abrogated SAB's protective effects on cisplatin-induced acute kidney injury.\",\n      \"method\": \"DARTS (drug affinity responsive target stability), CETSA (cellular thermal shift assay), molecular docking, PRDX5 siRNA knockdown, cisplatin- and folic acid-induced AKI models in vivo and in vitro\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — direct binding confirmed by multiple biophysical methods plus functional rescue experiment; single lab\",\n      \"pmids\": [\"40654183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Stachyose (STA) inhibits PRDX5 enzyme activity and disrupts the PRDX5–NRF2 protein–protein interaction, leading to decreased NQO1 levels and accumulation of quinone radicals, ultimately inducing apoptosis of AR-inhibitor drug-tolerant persister cells and slowing CRPC progression.\",\n      \"method\": \"PRDX5 enzyme activity assay, PRDX5–NRF2 interaction disruption assay, NQO1 Western blotting, apoptosis assay, pharmacokinetic analysis in CRPC mouse model\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct enzymatic inhibition demonstrated plus mechanistic downstream pathway validated in vivo; single lab\",\n      \"pmids\": [\"39168191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Porcine PRDX5 (pPRDX5) inhibits inflammatory responses induced by TNF-α or PRRSV in porcine alveolar macrophages. Knockdown of endogenous pPRDX5 enhanced inflammatory responses. The anti-inflammatory activity of pPRDX5 depends on its peroxidase activity, as shown by activity-dependent modulation experiments.\",\n      \"method\": \"Recombinant pPRDX5 protein treatment, siRNA knockdown of endogenous pPRDX5, TNF-α and PRRSV stimulation, inflammatory marker measurement, peroxidase activity assays\",\n      \"journal\": \"Developmental and comparative immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function with mechanistic link to peroxidase activity; ortholog but functional context consistent with mammalian PRDX5\",\n      \"pmids\": [\"35985565\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRDX5 is the unique atypical 2-Cys peroxiredoxin in mammals that reduces alkyl hydroperoxides, H2O2, and peroxynitrite (rate constant ~10^7 M⁻¹s⁻¹) via a catalytic cycle in which the peroxidatic Cys47 is oxidized by the peroxide substrate and then forms an intramolecular disulfide with the resolving Cys152, recycled by thioredoxin but not glutaredoxin; its 1.5 Å crystal structure confirmed the thioredoxin-fold monomer and the 13.8 Å separation of the two catalytic cysteines requiring a conformational change upon oxidation; PRDX5 is targeted to mitochondria, peroxisomes, cytosol, and nucleus by distinct targeting sequences, and functionally protects cells from nitro-oxidative stress, suppresses TNF-α-induced JNK activation and p53-induced apoptosis, regulates the DNA damage response through the ATM/Plk1/Sirt2/p53 axis, coordinates mitochondrial transport (via Rhot1/Trak1) and myonuclear positioning during myogenesis, acts downstream of SIRT3 in neuronal protection, modulates M1 macrophage polarization via TLR4/NF-κB, and physically interacts with Nrf2 to promote NQO1 expression and drug resistance in cancer; acetylation of PRDX5 inhibits its antioxidant activity, and its mitochondrial translocation is controlled by IER3 via the Parl protease.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PRDX5 is an atypical 2-Cys peroxiredoxin that functions as a thiol-dependent peroxidase detoxifying H2O2 and alkyl hydroperoxides, while also serving as a redox-sensing hub coupling ROS metabolism to transcriptional, inflammatory, and DNA damage signaling pathways. The enzyme localizes to mitochondria and peroxisomes — the latter via a C-terminal PTS1 signal that directly binds the receptor PEX5 — and its catalytic peroxidase activity is required for its anti-inflammatory function [PMID:10521424, PMID:10514471, PMID:35985565]. PRDX5 physically interacts with Nrf2 to promote NQO1 expression under oxidative stress, interacts with TFAM to maintain mitochondrial homeostasis, and modulates the DNA damage response through a Plk1/ATM–Sirt2/p53 axis while inducing autophagy to recycle DDR factors [PMID:31899687, PMID:39955823, PMID:36067023]. In myotubes, mitochondrial PRDX5 regulates nuclear positioning during myogenesis by controlling transcription of the mitochondrial transport regulators Rhot1 and Trak1, and its activity is negatively regulated by acetylation and positively regulated by the upstream deacetylase SIRT3 [PMID:41147088, PMID:41740330, PMID:40818507].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"The fundamental question of PRDX5's enzymatic identity was resolved: it is a mammalian peroxiredoxin with intrinsic peroxidase and antioxidant activity, targeted to both mitochondria and peroxisomes via a PTS1 signal recognized by PEX5.\",\n      \"evidence\": \"Reconstituted peroxidase activity from recombinant protein in vitro, GFP-fusion localization in HepG2, mutagenesis of PTS1 signal abolishing PEX5 binding\",\n      \"pmids\": [\"10521424\", \"10514471\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic mechanism and identity of the resolving Cys not addressed\", \"Relative contribution of mitochondrial vs. peroxisomal pools to cellular ROS defense unknown\", \"Endogenous substrate specificity beyond H2O2 not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Whether PRDX5's active site is druggable was established by NMR fragment screening, mapping small-molecule binding modes to the catalytic pocket.\",\n      \"evidence\": \"STD-NMR and 15N-HSQC chemical shift perturbation on purified human PRDX5\",\n      \"pmids\": [\"25025339\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No lead compound or inhibitor emerged from the fragment screen\", \"Functional consequence of active-site binding on peroxidase kinetics not measured\", \"Selectivity over other peroxiredoxin family members not determined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"PRDX5's role was extended beyond enzymatic ROS scavenging to a signaling adaptor function: it physically interacts with Nrf2 under oxidative stress and promotes downstream NQO1 expression, placing PRDX5 in the antioxidant transcriptional response.\",\n      \"evidence\": \"Co-immunoprecipitation in H2O2-stimulated NSCLC cells, NQO1 Western blotting; replicated and extended in 2023 and 2024 studies\",\n      \"pmids\": [\"31899687\", \"37305326\", \"39168191\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect nature of the PRDX5-Nrf2 interaction not resolved (no in vitro reconstitution with purified proteins)\", \"Mechanism by which PRDX5 enhances Nrf2 transcriptional activity unknown\", \"Whether the interaction depends on the oxidation state of PRDX5 catalytic cysteines is untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The question of whether PRDX5's anti-inflammatory activity is dependent on its peroxidase catalytic activity was answered affirmatively, separating enzymatic from non-enzymatic functions.\",\n      \"evidence\": \"Peroxidase-deficient mutant of porcine PRDX5 failed to suppress TNF-α- and PRRSV-induced inflammation in macrophages\",\n      \"pmids\": [\"35985565\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific catalytic residue(s) mutated and their structural consequences not fully detailed\", \"Whether peroxidase activity is similarly required for human PRDX5 anti-inflammatory effects not confirmed\", \"Downstream signaling pathway linking peroxidase activity to inflammatory suppression not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"PRDX5 was placed in the DNA damage response: its depletion induces γ-H2AX and 53BP1 foci, operating through Plk1-mediated ATM phosphorylation and a novel Sirt2-dependent p53 deacetylation axis, while also inducing autophagy for DDR molecule recycling.\",\n      \"evidence\": \"siRNA knockdown with Western blot and foci quantification, Sirt2 epistasis, autophagy assays in Pkd1-mutant cells\",\n      \"pmids\": [\"36067023\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PRDX5 acts directly on Plk1 or indirectly via ROS not distinguished\", \"Sirt2 as a p53-K382 deacetylase in this context awaits independent confirmation\", \"Connection to autophagy is correlative — molecular mechanism of DDR recycling undefined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A suite of studies established PRDX5 as a regulated mitochondrial hub: SIRT3 acts upstream to control PRDX5 levels in neurons; IER3/PARL controls PRDX5 mitochondrial translocation; PRDX5 interacts with TFAM to maintain mitochondrial homeostasis; and acetylation acts as a negative switch on PRDX5 antioxidant function.\",\n      \"evidence\": \"Sirt3-KO transcriptomics and PRDX5-silencing epistasis; IER3-KO with PARL co-IP and PRDX5 mitochondrial level measurement; PRDX5-TFAM co-IP with TFAM-KD epistasis; pharmacological acetylation modulation (NAM/NRC) with functional readouts\",\n      \"pmids\": [\"40818507\", \"41359162\", \"39955823\", \"41740330\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether SIRT3 directly deacetylates PRDX5 or acts indirectly is not established\", \"PARL's proteolytic processing of PRDX5 is inferred but cleavage site not identified\", \"Acetylation site(s) on PRDX5 that regulate activity are not mapped\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"PRDX5's role was extended to a tissue-specific structural function: in myotubes it regulates myonuclear positioning by controlling transcription of mitochondrial transport regulators Rhot1 and Trak1, linking mitochondrial redox status to cytoskeletal organization during myogenesis.\",\n      \"evidence\": \"Prdx5-KO mouse with grip strength and treadmill phenotypes, confocal/SIM imaging of nuclear positioning, Seahorse OCR, Rhot1/Trak1 RT-qPCR, siRNA epistasis\",\n      \"pmids\": [\"41147088\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PRDX5 peroxidase activity controls Rhot1/Trak1 transcription is unknown — transcription factor intermediary not identified\", \"Whether the nuclear positioning defect is ROS-dependent or redox-independent not tested\", \"Relevance to human myopathies not established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"PRDX5 was shown to promote M1 macrophage polarization through TLR4/NF-κB signaling, and separately to form stress-induced oligomers with potential chaperone activity in sperm, broadening its functional repertoire beyond classical peroxidase activity.\",\n      \"evidence\": \"siRNA knockdown with flow cytometry and NF-κB readouts in macrophages; imaging flow cytometry and native PAGE detecting PRDX5 oligomers in bull sperm\",\n      \"pmids\": [\"40015209\", \"39780184\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"TLR4 interaction with PRDX5 is from a single co-detection without reciprocal validation\", \"Chaperone activity of PRDX5 oligomers is inferred from oligomer formation — no direct chaperone assay performed\", \"Whether M1-polarizing function is conserved across species and tissues is untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis and specific acetylation/deacetylation sites governing PRDX5 activity; whether SIRT3 directly deacetylates PRDX5; the transcription factor(s) mediating PRDX5's control of Rhot1/Trak1 expression; and whether the Nrf2 interaction is direct or requires a bridging partner.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No crystal structure of PRDX5 in complex with any of its reported partners (Nrf2, TFAM, TLR4)\", \"Acetylation sites on PRDX5 remain unmapped\", \"In vivo genetic validation of the PRDX5–Nrf2 axis is lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016209\", \"supporting_discovery_ids\": [0, 1, 14]},\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 12, 13]},\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 3, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 5, 6, 7, 10]},\n      {\"term_id\": \"GO:0005777\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0016209\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [0, 1, 8, 13, 14]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11, 14]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 4, 11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PEX5\", \"NRF2\", \"TFAM\", \"SIRT3\", \"TLR4\", \"SIRT2\"],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"PRDX5 is the sole mammalian atypical 2-Cys peroxiredoxin, functioning as a broad-spectrum peroxidase that reduces alkyl hydroperoxides, H₂O₂, and peroxynitrite (rate constant ~10⁷ M⁻¹s⁻¹) through a catalytic cycle in which the peroxidatic Cys47 is oxidized to sulfenic acid, forms an intramolecular disulfide with the resolving Cys152 (separated by 13.8 Å in the reduced crystal structure, requiring conformational change), and is recycled by thioredoxin [PMID:10751410, PMID:11518528, PMID:15280035]. Distributed across mitochondria, peroxisomes, cytosol, and nucleus via distinct targeting sequences, PRDX5 protects cells from nitro-oxidative stress and suppresses TNF-α–induced JNK activation and p53-induced apoptosis; its mitochondrial import is controlled by IER3 through the Parl protease, and its activity is negatively regulated by acetylation [PMID:10521424, PMID:10751410, PMID:41359162, PMID:41740330]. Beyond canonical antioxidant defense, PRDX5 physically interacts with Nrf2 to promote NQO1 expression and drug resistance in cancer, operates downstream of SIRT3 in neuroprotection, modulates M1 macrophage polarization via TLR4/NF-κB, regulates the DNA damage response through the ATM/Plk1/Sirt2/p53 axis, and coordinates mitochondrial transport and myonuclear positioning during myogenesis through transcriptional regulation of Rhot1 and Trak1 [PMID:31899687, PMID:36067023, PMID:40818507, PMID:40015209, PMID:41147088]. PRDX5 upregulation in drug-tolerant persister cells promotes castration-resistant prostate cancer, and disruption of its interaction with NRF2 restores drug sensitivity [PMID:38115765, PMID:39168191].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of PRDX5 as a novel mammalian peroxiredoxin with dual mitochondrial and peroxisomal targeting established that mammals possess a peroxiredoxin distinct from the known typical 2-Cys family members, with peroxisomal import mediated by PTS1 signal recognition by PEX5.\",\n      \"evidence\": \"Recombinant expression, GFP-fusion localization in HepG2, PEX5 binding assays with PTS1 mutagenesis\",\n      \"pmids\": [\"10521424\", \"10514471\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cytosolic and nuclear targeting mechanisms not yet defined\", \"Endogenous substrates in each compartment unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defining the atypical 2-Cys catalytic mechanism — intramolecular disulfide between Cys48 and Cys152, recycled by thioredoxin but not glutaredoxin — resolved how PRDX5 differs mechanistically from all other mammalian peroxiredoxins and established its first cellular function: suppression of TNF-α–induced JNK activation and p53-induced apoptosis.\",\n      \"evidence\": \"Site-directed mutagenesis of each Cys, thioredoxin-dependent peroxidase assays, overexpression in NIH 3T3 (JNK readout) and mammalian cells (p53-apoptosis readout)\",\n      \"pmids\": [\"10751410\", \"10679306\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for intramolecular disulfide formation not yet available\", \"Mechanism of p53-apoptosis inhibition beyond ROS scavenging unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"The 1.5 Å crystal structure of reduced PRDX5 revealed a thioredoxin-fold monomer with 13.8 Å separation between catalytic cysteines, demonstrating that a major conformational change must accompany oxidation — explaining why the enzyme is monomeric rather than forming the obligate dimers seen in typical 2-Cys peroxiredoxins.\",\n      \"evidence\": \"X-ray crystallography at 1.5 Å resolution\",\n      \"pmids\": [\"11518528\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Oxidized-form structure not captured\", \"Conformational dynamics during catalysis unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Pulse radiolysis measurement of the peroxynitrite reduction rate constant (~7×10⁷ M⁻¹s⁻¹) established PRDX5 as one of the fastest biological peroxynitrite reductases, expanding its functional role from H₂O₂ scavenging to reactive nitrogen species defense.\",\n      \"evidence\": \"Pulse radiolysis kinetics with Cys mutants\",\n      \"pmids\": [\"15280035\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution to peroxynitrite scavenging in vivo versus other reductases untested\", \"Compartment-specific kinetics not measured\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"In vivo gain-of-function via adenoviral PRDX5 overexpression in rat liver transplantation demonstrated that PRDX5 protects against ischemia-reperfusion injury, extending its antioxidant role to a whole-organ pathological context.\",\n      \"evidence\": \"Adenoviral overexpression in small-for-size rat liver grafts with survival analysis\",\n      \"pmids\": [\"20451279\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream signaling pathway mediating hepatoprotection not defined\", \"Loss-of-function in this model not performed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Discovery of the PRDX5–Nrf2 physical interaction revealed a non-canonical signaling role: PRDX5 promotes NQO1 expression under oxidative stress, and STAT3 transcriptionally upregulates PRDX5 via promoter hypomethylation, positioning PRDX5 within a STAT3→PRDX5→Nrf2 signaling axis that promotes EMT and drug resistance in NSCLC.\",\n      \"evidence\": \"Co-immunoprecipitation, ChIP for STAT3 binding at PRDX5 promoter, bisulfite sequencing, siRNA/overexpression with EMT markers\",\n      \"pmids\": [\"31899687\", \"33416106\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Binding interface between PRDX5 and Nrf2 unmapped\", \"Whether PRDX5 redox activity is required for Nrf2 interaction unknown\", \"Reciprocal Co-IP for PRDX5–Nrf2 not shown in original report\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Porcine PRDX5 demonstrated peroxidase-activity-dependent anti-inflammatory function in macrophages stimulated with TNF-α or PRRSV, providing direct evidence that PRDX5's enzymatic activity (not merely protein presence) underlies its immunomodulatory effects.\",\n      \"evidence\": \"Recombinant protein treatment and siRNA knockdown in porcine alveolar macrophages with peroxidase activity-dependence assays\",\n      \"pmids\": [\"35985565\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking peroxidase activity to inflammatory signaling not identified\", \"Cross-species generalizability to human macrophages not confirmed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"PRDX5 was placed within the DNA damage response pathway operating through ATM/Plk1/Sirt2/p53, with Sirt2 identified as a novel PRDX5-dependent p53 K382 deacetylase, and separately shown to promote castration-resistant prostate cancer via its role in drug-tolerant persister cell survival.\",\n      \"evidence\": \"siRNA knockdown with γ-H2AX/53BP1 readouts, p53 acetylation assays in Pkd1 mutant cells; PRDX5 inhibition in CRPC animal models\",\n      \"pmids\": [\"36067023\", \"38115765\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physical interaction between PRDX5 and Sirt2 not demonstrated\", \"How PRDX5 peroxidase activity connects to DDR signaling mechanistically unclear\", \"Whether DDR and CRPC roles converge on a shared mechanism unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Pharmacological disruption of the PRDX5–NRF2 protein–protein interaction by stachyose validated this complex as a druggable node: inhibiting PRDX5 enzymatic activity and NRF2 binding decreased NQO1 levels and induced apoptosis of drug-resistant persister cells in CRPC models.\",\n      \"evidence\": \"Enzyme activity assays, interaction disruption assays, NQO1 immunoblotting, apoptosis readout, CRPC mouse pharmacokinetics\",\n      \"pmids\": [\"39168191\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of stachyose–PRDX5 binding undefined\", \"Selectivity of stachyose for PRDX5 over other peroxiredoxins untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Multiple 2025 studies expanded PRDX5 from a simple antioxidant to a multifunctional signaling hub: genetic knockout revealed its requirement for mitochondrial transport (Rhot1/Trak1) and myonuclear positioning during myogenesis; epistasis experiments placed it downstream of SIRT3 in neuroprotection; IER3 was shown to control its mitochondrial import via Parl protease; and acetylation was identified as a direct negative regulator of its activity.\",\n      \"evidence\": \"Prdx5⁻/⁻ and Prdx3⁻/⁻;Prdx5⁻/⁻ mice with Seahorse/microscopy/Rhot1-Trak1 knockdown; SIRT3 agonist plus PRDX5 siRNA epistasis in SCI model; IER3 KO mice with Co-IP of IER3–Parl; OGD/R with acetylation modulation in retinal neurons; TLR4/NF-κB pathway in macrophage polarization\",\n      \"pmids\": [\"41147088\", \"40818507\", \"41359162\", \"41740330\", \"40015209\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Acetylation site(s) on PRDX5 not mapped\", \"Whether SIRT3 directly deacetylates PRDX5 not tested\", \"How Parl cleavage enables mitochondrial import structurally unresolved\", \"Integration of myogenesis and immune roles into a unified regulatory model lacking\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include: the identity of the acetyltransferase/deacetylase pair controlling PRDX5 activity, the structural basis of the PRDX5–Nrf2 interaction and whether it requires PRDX5's redox state, the oxidized-form crystal structure capturing the conformational change, and how PRDX5's compartment-specific functions are differentially regulated.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No oxidized-state crystal structure available\", \"Acetylation sites and modifying enzymes unidentified\", \"Compartment-specific knockout or targeting studies lacking\", \"PRDX5–Nrf2 binding interface and redox dependence unmapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016209\", \"supporting_discovery_ids\": [0, 1, 2, 5, 6, 7]},\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 2, 6, 7]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [9, 11, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 2, 7, 15, 16]},\n      {\"term_id\": \"GO:0005777\", \"supporting_discovery_ids\": [0, 1, 7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 7]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [2, 7, 8, 20]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [3, 20]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [19, 23]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9, 10, 19]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"NRF2\",\n      \"TFAM\",\n      \"SIRT3\",\n      \"PARL\",\n      \"IER3\",\n      \"TLR4\",\n      \"PEX5\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}